TG (Thyroglobulin) variants and mutations
TG (also known as Thyroglobulin) is a human protein-coding gene encoding a thyroglobulin protein. It provides the large iodinated scaffold on which thyroid hormones are synthesized and stored within thyroid follicles. Biallelic or dominant pathogenic variants can impair hormone production and cause congenital hypothyroidism, often with goiter. This analysis covers 4,024 TG variants and mutations. Of these, 85% have computational variant effect predictions. Disease context includes hypothyroidism, familial thyroid dyshormonogenesis, and Hashimoto thyroiditis. Example TG variants include M1?, M1I, and A2V.
Variant analysis overview
- Gene: TG
- Protein: Thyroglobulin
- UniProt accession: P01266
- Organism: Homo sapiens
- Variants analyzed: 4024
- Variant scope: all variants
- Completed: 2026-08-20
Variant and mutation evidence
- Variant composition: 3,823 unspecified-consequence records; 14 frameshift variants; 98 missense variants; 78 synonymous variants; 4 stop-gained variants; 3 splice-region variants; 2 in-frame deletions; 1 in-frame insertions; 1 substitution
- Prediction scores: 3,421 variants have prediction scores (85% of the analyzed set).
Clinical, disease, and population context
- Disease context: 25 disease associations are represented. Top associations: hypothyroidism, familial thyroid dyshormonogenesis, Hashimoto thyroiditis, thyroid gland disorder, congenital hypothyroidism, nodular goiter, nontoxic goiter, multinodular goiter, toxic multinodular goitre, thyroid gland carcinoma, thyrotoxicosis, goiter.
Protein structure and variant hotspots
- Protein features: 11 domains; 57 post-translational modification sites.
- Structural context: 1,499 variants have structural context.
- PTM context: 66 variants overlap post-translational modification sites.
Data sources
Evidence in this analysis draws on EBI Proteins Variation, UniProt, gnomAD v4, EuropePMC, 3D Hotspot Analysis, Interaction Network Analysis, Protein Data Bank, gnomAD constraint, Open Targets, MaveDB, LitVar.
Notable TG variants
Examples include M1?, M1I, A2V, A2S, A2T, A2G, A2D, A2A. Listed records include available protein-change notation, database identifiers, clinical classifications, computational predictions, population evidence, experimental measurements, and disease context.
- M1?, NCI-TCGA Cosmic COSV5508, Variant assessed as somatic; high impact.
- M1I (p.Met1Ile), rs2132013784, ClinGen CA372243968, ClinVar RCV001808184, MetaLR 0.17, MetaSVM -0.75, Uncertain significance, Iodotyrosyl coupling defect
- A2V (p.Ala2Val), NCI-TCGA Cosmic COSV9960, REVEL 0.04, MetaLR 0.16, Variant assessed as somatic; moderate impact.
- A2S (p.Ala2Ser), gnomAD 8-132867004-G-T, REVEL 0.04, MetaLR 0.15
- A2T (p.Ala2Thr), gnomAD 8-132867004-G-A, REVEL 0.02, MetaLR 0.15
- A2G (p.Ala2Gly), gnomAD 8-132867005-C-G, REVEL 0.03, MetaLR 0.14
- A2D (p.Ala2Asp), gnomAD 8-132867005-C-A, REVEL 0.18, MetaLR 0.18
- A2A (p.Ala2Ala), rs1420201079, gnomAD 8-132867006-C-T, CADD 9.17
- L3M (p.Leu3Met), rs1256883610, TOPMed rs1256883610, gnomAD rs1256883610, REVEL 0.03, MetaLR 0.15, Variant assessed as somatic; moderate impact.
- L3P (p.Leu3Pro), ExAC rs755500716, gnomAD rs755500716, REVEL 0.28, MetaLR 0.19
- L3W (p.Leu3Trp), gnomAD 8-132867004-GC-G, CADD 22.80
- L3V (p.Leu3Val), gnomAD 8-132867007-C-G, REVEL 0.04, MetaLR 0.13
- L3L (p.Leu3Leu), rs1054137706, gnomAD 8-132867009-G-T, CADD 6.03
- V4F (p.Val4Phe), gnomAD 8-132867010-G-T, REVEL 0.08, MetaLR 0.13
- V4I (p.Val4Ile), gnomAD 8-132867010-G-A, REVEL 0.11, MetaLR 0.14
- V4A (p.Val4Ala), gnomAD 8-132867011-T-C, REVEL 0.05, MetaLR 0.10
- V4V (p.Val4Val), gnomAD 8-132867012-C-A, CADD 5.79
- L5M (p.Leu5Met), ExAC rs779302988, TOPMed rs779302988, gnomAD rs779302988, REVEL 0.17, MetaLR 0.29
- L5P (p.Leu5Pro), TOPMed rs1316252643, gnomAD rs1316252643, REVEL 0.14, MetaLR 0.18, Uncertain significance, not specified
- L5L (p.Leu5Leu), rs779302988, gnomAD 8-132867013-C-T, CADD 6.12
- E6A (p.Glu6Ala), NCI-TCGA TCGA novel, Variant assessed as somatic; high impact.
- E6* (p.Glu6Ter), gnomAD 8-132867016-G-T, CADD 33.00
- E6G (p.Glu6Gly), gnomAD 8-132867017-A-G, REVEL 0.09, MetaLR 0.09
- E6D (p.Glu6Asp), gnomAD 8-132867018-G-T, REVEL 0.13, MetaLR 0.11
- I7N (p.Ile7Asn), gnomAD 8-132867020-T-A, REVEL 0.08, MetaLR 0.12
- I7I (p.Ile7Ile), rs1838989928, gnomAD 8-132867021-C-T, CADD 3.87
- F8S (p.Phe8Ser), rs1403969743, NCI-TCGA Cosmic COSV9960, gnomAD rs1403969743, AlphaMissense 0.12, MetaLR 0.08, Variant assessed as somatic; moderate impact.
- F8L (p.Phe8Leu), gnomAD 8-132867024-C-A, REVEL 0.04, MetaLR 0.08
- T9I (p.Thr9Ile), rs1332458708, ClinGen CA372244091, ClinVar RCV004474446, gnomAD rs1332458708, REVEL 0.07, MetaLR 0.15, Uncertain significance, Inborn genetic diseases
- T9P (p.Thr9Pro), Ensembl rs1587143065, REVEL 0.14, MetaLR 0.12
- T9A (p.Thr9Ala), gnomAD 8-132867025-A-G, REVEL 0.10, MetaLR 0.11
- T9T (p.Thr9Thr), gnomAD 8-132867027-C-A, CADD 1.06
- L10P (p.Leu10Pro), ESP rs376079122, TOPMed rs376079122, gnomAD rs376079122, REVEL 0.53, MetaLR 0.39, Likely benign, not specified
- L10C (p.Leu10Cys), gnomAD 8-132867025-AC-A, CADD 11.80
- L10M (p.Leu10Met), gnomAD 8-132867028-C-A, REVEL 0.29, MetaLR 0.36
- L10V (p.Leu10Val), gnomAD 8-132867028-C-G, REVEL 0.27, MetaLR 0.31
- L10Q (p.Leu10Gln), gnomAD 8-132867029-T-A, REVEL 0.51, MetaLR 0.39
- L10L (p.Leu10Leu), gnomAD 8-132867030-G-T, CADD 2.21
- L11P (p.Leu11Pro), gnomAD rs1278421972, REVEL 0.46, MetaLR 0.33
- L11M (p.Leu11Met), gnomAD 8-132867031-C-A, REVEL 0.13, MetaLR 0.30
- L11L (p.Leu11Leu), gnomAD 8-132867031-C-T, CADD 4.96
- L11Q (p.Leu11Gln), gnomAD 8-132867032-T-A, REVEL 0.38, MetaLR 0.34
- A12S (p.Ala12Ser), NCI-TCGA TCGA novel, REVEL 0.06, MetaLR 0.07, Variant assessed as somatic; moderate impact.
- A12T (p.Ala12Thr), gnomAD 8-132867034-G-A, REVEL 0.05, MetaLR 0.09
- A12D (p.Ala12Asp), gnomAD 8-132867035-C-A, REVEL 0.13, MetaLR 0.10
- A12A (p.Ala12Ala), gnomAD 8-132867036-C-T, CADD 5.40
- S13C (p.Ser13Cys), ExAC rs753032118, gnomAD rs753032118, REVEL 0.15, MetaLR 0.21
- S13F (p.Ser13Phe), ExAC rs753032118, gnomAD rs753032118, REVEL 0.26, MetaLR 0.15
- S13P (p.Ser13Pro), gnomAD 8-132867037-T-C, REVEL 0.30, MetaLR 0.13
- S13Y (p.Ser13Tyr), gnomAD 8-132867038-C-A, REVEL 0.25, MetaLR 0.19
- S13S (p.Ser13Ser), rs1241452705, gnomAD 8-132867039-C-T, CADD 0.11
- I14L (p.Ile14Leu), 1000Genomes rs544043844, TOPMed rs544043844, gnomAD rs544043844, REVEL 0.04, MetaLR 0.12
- I14S (p.Ile14Ser), ExAC rs577354103, gnomAD rs577354103, REVEL 0.07, MetaLR 0.15
- I14T (p.Ile14Thr), ExAC rs577354103, gnomAD rs577354103, REVEL 0.07, MetaLR 0.15
- I14I (p.Ile14Ile), gnomAD 8-132867042-C-A, CADD 4.75
- C15F (p.Cys15Phe), TOPMed rs1268394257, gnomAD rs1268394257, REVEL 0.25, MetaLR 0.15
- C15S (p.Cys15Ser), TOPMed rs1268394257, gnomAD rs1268394257, REVEL 0.13, MetaLR 0.12
- C15Y (p.Cys15Tyr), TOPMed rs1268394257, gnomAD rs1268394257, REVEL 0.29, MetaLR 0.18
- C15C (p.Cys15Cys), gnomAD 8-132867045-C-T, CADD 4.35
- C15* (p.Cys15Ter), gnomAD 8-132867045-C-A, CADD 29.60
- W16* (p.Trp16Ter), rs780846892, ClinGen CA4882765, ClinVar RCV001170075, ExAC rs780846892, CADD 24.50, Pathogenic
- W16R (p.Trp16Arg), gnomAD 8-132867046-T-A, REVEL 0.10, MetaLR 0.09
- W16L (p.Trp16Leu), gnomAD 8-132867047-G-T, REVEL 0.06, MetaLR 0.06
- W16C (p.Trp16Cys), gnomAD 8-132867048-G-T, REVEL 0.15, MetaLR 0.09
- V17R (p.Val17Arg), rs1838989517, gnomAD 8-132867012-C-CCT, CADD 21.80
- V17M (p.Val17Met), gnomAD 8-132867049-G-A, REVEL 0.17, MetaLR 0.28
- S18L (p.Ser18Leu), ExAC rs745469083, TOPMed rs745469083, gnomAD rs745469083, REVEL 0.09, MetaLR 0.17, Uncertain significance, Inborn genetic diseases
- S18* (p.Ser18Ter), gnomAD 8-132867053-C-A, CADD 33.00
- S18S (p.Ser18Ser), gnomAD 8-132867054-G-C, CADD 0.03
- A19T (p.Ala19Thr), TOPMed rs866066332, REVEL 0.17, MetaLR 0.24
- A19S (p.Ala19Ser), gnomAD 8-132867055-G-T, REVEL 0.12, MetaLR 0.21
- A19D (p.Ala19Asp), gnomAD 8-132867056-C-A, REVEL 0.33, MetaLR 0.21
- A19A (p.Ala19Ala), gnomAD 8-132867057-C-A, CADD 6.49
- N20S (p.Asn20Ser), Ensembl rs1587143282, REVEL 0.32, MetaLR 0.29
- N20Y (p.Asn20Tyr), ExAC rs779612122, TOPMed rs779612122, gnomAD rs779612122, REVEL 0.51, MetaLR 0.34, Uncertain significance, not provided
- N20I (p.Asn20Ile), gnomAD 8-132867059-A-T, REVEL 0.42, MetaLR 0.34
- N20N (p.Asn20Asn), rs140030312, gnomAD 8-132867060-T-C, CADD 6.49
- I21V (p.Ile21Val), 1000Genomes rs574422251, TOPMed rs574422251, gnomAD rs574422251, REVEL 0.06, MetaLR 0.12
- I21N (p.Ile21Asn), gnomAD 8-132867062-T-A, REVEL 0.33, MetaLR 0.18
- I21I (p.Ile21Ile), gnomAD 8-132867063-C-A, CADD 8.42
- F22L (p.Phe22Leu), Ensembl rs1340994770, REVEL 0.23, MetaLR 0.12, Uncertain significance, Inborn genetic diseases
- F22I (p.Phe22Ile), gnomAD 8-132867064-T-A, REVEL 0.31, MetaLR 0.16
- F22F (p.Phe22Phe), rs143647619, gnomAD 8-132867066-C-T, CADD 2.50
- E23K (p.Glu23Lys), TOPMed rs1024568791, gnomAD rs1024568791, REVEL 0.34, MetaLR 0.32, Uncertain significance, Iodotyrosyl coupling defect
- E23Q (p.Glu23Gln), TOPMed rs1024568791, gnomAD rs1024568791, REVEL 0.29, MetaLR 0.31
- Y24C (p.Tyr24Cys), NCI-TCGA TCGA novel, REVEL 0.65, MetaLR 0.33, Variant assessed as somatic; moderate impact.
- Q25* (p.Gln25Ter), rs755777744, ClinGen CA372244625, ClinVar RCV003716805, CADD 39.00, Pathogenic
- Q25E (p.Gln25Glu), ExAC rs755777744, TOPMed rs755777744, gnomAD rs755777744, REVEL 0.08, MetaLR 0.16
- Q25K (p.Gln25Lys), ExAC rs755777744, TOPMed rs755777744, gnomAD rs755777744, REVEL 0.18, MetaLR 0.16
- V26L (p.Val26Leu), ExAC rs779477989, REVEL 0.07, MetaLR 0.14, Uncertain significance, Inborn genetic diseases
- V26M (p.Val26Met), ExAC rs779477989, REVEL 0.15, MetaLR 0.27
- V26V (p.Val26Val), rs1839141995, gnomAD 8-132868125-G-C, CADD 9.34
- D27N (p.Asp27Asn), NCI-TCGA Cosmic COSV9960, Variant assessed as somatic; moderate impact.
- D27V (p.Asp27Val), Ensembl rs930523065
- A28V (p.Ala28Val), rs114543085, ClinGen CA4882786, ClinVar RCV004526301, 1000Genomes rs114543085, REVEL 0.04, MetaLR 0.15, Uncertain significance, not specified
- A28D (p.Ala28Asp), gnomAD 8-132868130-C-A, REVEL 0.10, MetaLR 0.15
- Q29* (p.Gln29Ter), rs1554648860, ClinGen CA372244650, ClinVar RCV000521328, TOPMed rs1554648860, CADD 39.00, Pathogenic
- P30T (p.Pro30Thr), ExAC rs754496117, gnomAD rs754496117, REVEL 0.29, MetaLR 0.34
- P30R (p.Pro30Arg), gnomAD 8-132868136-C-G, REVEL 0.35, MetaLR 0.35
- P30P (p.Pro30Pro), rs779013905, gnomAD 8-132868137-C-T, CADD 2.62
- L31P (p.Leu31Pro), gnomAD rs1404590444, REVEL 0.47, MetaLR 0.44
- L31A (p.Leu31Ala), gnomAD 8-132868130-C-CCC, CADD 24.20
- L31F (p.Leu31Phe), gnomAD 8-132868138-C-T, REVEL 0.39, MetaLR 0.49
- R32C (p.Arg32Cys), rs371315184, ClinGen CA4882789, ClinVar RCV001161224, 1000Genomes rs371315184, REVEL 0.40, MetaLR 0.47, Uncertain significance, Iodotyrosyl coupling defect
- R32H (p.Arg32His), ESP rs146814857, ExAC rs146814857, TOPMed rs146814857, gnomAD rs146814857, REVEL 0.38, MetaLR 0.47
- R32R (p.Arg32Arg), rs1342577194, gnomAD 8-132868143-T-C, CADD 3.11
- P33L (p.Pro33Leu), NCI-TCGA Cosmic COSV5507, MetaLR 0.45, MetaSVM -0.06, Variant assessed as somatic; moderate impact.
- C34W (p.Cys34Trp), gnomAD 8-132868148-GT-G, CADD 16.20
- E35D (p.Glu35Asp), NCI-TCGA Cosmic COSV5508, MetaLR 0.45, MetaSVM -0.24, Variant assessed as somatic; moderate impact.
- E35E (p.Glu35Glu), rs374559000, gnomAD 8-132868152-G-A, CADD 9.78
- L36R (p.Leu36Arg), gnomAD 8-132868154-T-G, REVEL 0.28, MetaLR 0.28
- L36P (p.Leu36Pro), gnomAD 8-132868154-T-C, REVEL 0.47, MetaLR 0.43
- L36L (p.Leu36Leu), rs1277880911, gnomAD 8-132868155-G-T, CADD 10.30
- Q37H (p.Gln37His), NCI-TCGA Cosmic COSV5507, Variant assessed as somatic; moderate impact.
- Q37Q (p.Gln37Gln), gnomAD 8-132868158-G-A, CADD 9.43
- R38K (p.Arg38Lys), TOPMed rs1839144302, gnomAD rs1839144302, REVEL 0.60, MetaLR 0.45
- R38R (p.Arg38Arg), rs747248982, gnomAD 8-132868159-A-C, CADD 11.70
- E39* (p.Glu39Ter), ExAC rs771157696, TOPMed rs771157696, gnomAD rs771157696, CADD 39.00, Likely pathogenic
- E39G (p.Glu39Gly), rs776679893, ClinGen CA4882794, ClinVar RCV002661020, ExAC rs776679893, REVEL 0.42, MetaLR 0.34, Uncertain significance, Inborn genetic diseases
- E39K (p.Glu39Lys), ExAC rs771157696, TOPMed rs771157696, gnomAD rs771157696, REVEL 0.34, MetaLR 0.34, Likely pathogenic
- p.Glu39 Thr40del, gnomAD 8-132868160-GGGAA, CADD 19.30
- E39Q (p.Glu39Gln), gnomAD 8-132868162-G-C, REVEL 0.31, MetaLR 0.34
- E39E (p.Glu39Glu), rs140632677, gnomAD 8-132868164-A-G, CADD 3.07
- T40K (p.Thr40Lys), rs539574101, ClinGen CA4882797, ClinVar RCV002878755, ExAC rs539574101, REVEL 0.03, MetaLR 0.06, Uncertain significance, Inborn genetic diseases
- T40M (p.Thr40Met), ExAC rs539574101, TOPMed rs539574101, gnomAD rs539574101, REVEL 0.12, MetaLR 0.14, Uncertain significance
- T40T (p.Thr40Thr), rs368659212, gnomAD 8-132868167-G-A, CADD 9.39
- A41V (p.Ala41Val), TOPMed rs1839145695, gnomAD rs1839145695, REVEL 0.41, MetaLR 0.44, Uncertain significance, Inborn genetic diseases
- F42F (p.Phe42Phe), rs1262382386, gnomAD 8-132868173-T-C, CADD 4.74
- K44S (p.Lys44Ser), gnomAD 8-132868175-TG-T, CADD 24.90
- K44K (p.Lys44Lys), rs764500807, gnomAD 8-132868179-G-A, CADD 7.34
- Q45E (p.Gln45Glu), gnomAD 8-132868180-C-G, REVEL 0.05, MetaLR 0.15
- A46T (p.Ala46Thr), gnomAD rs1192657763, REVEL 0.13, MetaLR 0.24, Uncertain significance, Inborn genetic diseases
- A46Q (p.Ala46Gln), rs1458505722, gnomAD 8-132868180-CA-C, CADD 14.50
- A46E (p.Ala46Glu), gnomAD 8-132868184-C-A, REVEL 0.06, MetaLR 0.10
- A46A (p.Ala46Ala), rs751930232, gnomAD 8-132868185-A-G, CADD 2.40
- D47N (p.Asp47Asn), TOPMed rs1208857552, REVEL 0.12, MetaLR 0.20
- Y48C (p.Tyr48Cys), TOPMed rs1478582021, gnomAD rs1478582021, REVEL 0.55, MetaLR 0.63
- Y48Y (p.Tyr48Tyr), rs114436500, gnomAD 8-132868191-C-T, CADD 2.88
- V49A (p.Val49Ala), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- V49M (p.Val49Met), rs371271403, ClinGen CA4882802, ClinVar RCV004474439, ESP rs371271403, REVEL 0.32, MetaLR 0.46, Uncertain significance, Inborn genetic diseases
- V49V (p.Val49Val), rs753380674, gnomAD 8-132868194-G-C, CADD 0.21
- P50T (p.Pro50Thr), TOPMed rs1839148182, MetaLR 0.90, MetaSVM 1.12
- P50P (p.Pro50Pro), rs568899502, gnomAD 8-132868197-C-T, CADD 5.75
- Q51* (p.Gln51Ter), rs1839148591, ClinGen CA372244894, ClinVar RCV003672487, TOPMed rs1839148591, CADD 37.00, Pathogenic
- Q51L (p.Gln51Leu), gnomAD 8-132868199-A-T, REVEL 0.66, MetaLR 0.51
- A53S (p.Ala53Ser), TOPMed rs1324784516, gnomAD rs1324784516, REVEL 0.03, MetaLR 0.07
- A53T (p.Ala53Thr), NCI-TCGA TCGA novel, MetaLR 0.07, MetaSVM -1.03, Variant assessed as somatic; moderate impact.
- A53E (p.Ala53Glu), gnomAD 8-132868205-C-A, REVEL 0.10, MetaLR 0.13
- E54D (p.Glu54Asp), TOPMed rs1404981492, gnomAD rs1404981492, REVEL 0.33, MetaLR 0.26
- E54Q (p.Glu54Gln), rs1303871583, ClinGen CA372244926, ClinVar RCV001161228, ClinVar RCV005503019, REVEL 0.40, MetaLR 0.40, Uncertain significance, Inborn genetic diseases; Iodotyrosyl coupling defect
- E54E (p.Glu54Glu), gnomAD 8-132868209-G-A, CADD 0.97
- D55H (p.Asp55His), Ensembl rs1050036878, MetaLR 0.46, MetaSVM -0.05, Uncertain significance, Inborn genetic diseases
- D55N (p.Asp55Asn), gnomAD 8-132868210-G-A, REVEL 0.31, MetaLR 0.32
- G56S (p.Gly56Ser), NCI-TCGA Cosmic COSV9960, REVEL 0.90, MetaLR 0.94, Variant assessed as somatic; moderate impact.
- G56A (p.Gly56Ala), gnomAD 8-132868212-TG-T, CADD 30.00
- S57N (p.Ser57Asn), ExAC rs754545420, gnomAD rs754545420
- S57S (p.Ser57Ser), rs778494974, gnomAD 8-132868218-C-T, CADD 7.46
- F58L (p.Phe58Leu), ExAC rs748159184, TOPMed rs748159184, gnomAD rs748159184, REVEL 0.71, MetaLR 0.57
- Q59H (p.Gln59His), gnomAD rs1239281001, REVEL 0.27, MetaLR 0.29
- Q59R (p.Gln59Arg), ESP rs151097288, MetaLR 0.08, MetaSVM -1.06
- Q59Q (p.Gln59Gln), gnomAD 8-132869729-G-A, CADD 17.00
- T60A (p.Thr60Ala), gnomAD rs1286496966, REVEL 0.18, MetaLR 0.10
- T60I (p.Thr60Ile), Ensembl rs1839300363, MetaLR 0.42, MetaSVM -0.52
- T60T (p.Thr60Thr), gnomAD 8-132869732-T-C, CADD 0.44
- V61I (p.Val61Ile), gnomAD 8-132869733-G-A, REVEL 0.05, MetaLR 0.15
- Q62K (p.Gln62Lys), rs1839300540, ClinGen CA372245824, ClinVar RCV004555652, Ensembl rs1839300540, AlphaMissense 0.71, MetaLR 0.76, Uncertain significance, TG-related disorder
- Q62Q (p.Gln62Gln), rs1262235663, gnomAD 8-132869738-G-A, CADD 7.10
- C63Y (p.Cys63Tyr), NCI-TCGA TCGA novel, MetaLR 0.87, MetaSVM 1.01, Variant assessed as somatic; moderate impact.
- C63F (p.Cys63Phe), gnomAD 8-132869740-G-T, REVEL 0.91, MetaLR 0.86
- Q64Q (p.Gln64Gln), gnomAD 8-132869744-G-A, CADD 5.47
- N65T (p.Asn65Thr), NCI-TCGA Cosmic COSV9960, Variant assessed as somatic; moderate impact.
- N65Y (p.Asn65Tyr), ExAC rs764894011, gnomAD rs764894011, REVEL 0.16, MetaLR 0.26
- N65K (p.Asn65Lys), gnomAD 8-132869747-C-A, REVEL 0.04, MetaLR 0.08
- N65N (p.Asn65Asn), rs370206088, gnomAD 8-132869747-C-T, CADD 0.17
- D66A (p.Asp66Ala), TOPMed rs1186537684, gnomAD rs1186537684, MetaLR 0.11, MetaSVM -1.00
- D66G (p.Asp66Gly), TOPMed rs1186537684, gnomAD rs1186537684, REVEL 0.09, MetaLR 0.10
- D66N (p.Asp66Asn), rs1245830644, NCI-TCGA Cosmic COSV5506, TOPMed rs1245830644, gnomAD rs1245830644, REVEL 0.06, MetaLR 0.10, Uncertain significance, Inborn genetic diseases
- D66Y (p.Asp66Tyr), gnomAD 8-132869748-G-T, REVEL 0.20, MetaLR 0.27
- D66D (p.Asp66Asp), rs141082783, gnomAD 8-132869750-C-T, CADD 0.08
- D66E (p.Asp66Glu), gnomAD 8-132869750-C-A, REVEL 0.17, MetaLR 0.10
Public TG analysis runs
- TG analysis run — TG (4,024 variants) — completed 2026-08-20